rafaelercII escribió:OXiGENE Presenta datos que confirmen el beneficio de supervivencia de ZYBRESTAT en pacientes con cáncer de tiroides anaplásico
ok, pero este tumor es muy muy muy infrecuente
lo bueno (y altamente probable) es que sirva en otros canceres...............ahi si, agarrate.............
.se la va a comprar Roche, o AZN...........
Zybrestat - Vascular Disrupting Agent and Cancer Therapy
Email Article Print Link To Us Related Projects Key Data
Drug (Brand/Generic)Zybrestat (combretastatin A4 phosphate)Company/LicenseeOxigeneTherapy ClassVDAProduct D
Prodrug designed to destroy tumour blood supplyCurrent Indicationanaplastic thyroid
A member of a new class of anti-cancer drugs, Zybrestat is in Phase II/III trials under a special protocol assessment agreement with the US Food and Drug Administartion (FDA).
"VDAs differ from angiogenesis inhibitors in that they are designed to attack the established blood vessel network within a tumour."Zybrestat (
combretastatin A4 phosphate) is a prodrug that is converted to combretastatin inside the endothelial cells that line blood vessels. Combretastatin has a dual-mode of action, targeting both VE-cadherin, a junction protein that is important for endothelial cell survival, and the associated beta-catenin/AKT signalling pathway.
As a rCombining VDAs with angiogenesis inhibitors
The potential to use VDAs in combination with angiogenic inhibitors is a concept that is attracting considerable interest among scientists. Targeting different aspects of a tumour’s blood supply, sequential use of VDAs and angiogenic inhibitors could lead to massive tumour necrosis and destruction.
While a VDA such as Zybrestat could be used to destroy the established blood supply feeding the tumour, the subsequent addition of an angiogenic inhibitor could prevent the regrowth of blood vessels (neovascularisation) which allows a tumour to survive and proliferate following initial therapy. Preventing the regrowth of blood vessels from the viable tumour rim could help stop tumours from spreading.
Oxigene’s Zybrestat is under development for the treatment of anaplastic thyroid cancer, a highly aggressive primary thyroid malignancy for which there are no approved treatments.
Currently, newly diagnosed patients have a median life expectancy of about three months. Although relatively rare, it represents a disease of significant unmet clinical need. VDAs, of which Zybrestat is one of several in development, may have the potential to treat difficult malignancies such as anaplastic
thyroid cancer as well as other solid tumours when used in conjunction with established cancer drugs.
Combretastatin was first isolated from the bark of the African bush willow tree, which grows in the Eastern Cape region of South Africa.
